Journal of Clinical Endocrinology & Metabolism, Vol 63, 1270-1276, Copyright © 1986 by Endocrine Society

ARTICLES

Blockade of the spontaneous midcycle gonadotropin surge in monkeys by RU 486: a progesterone antagonist or agonist?

RL Collins and GD Hodgen

Preovulatory ovarian secretion of progesterone (P4), several hours before the onset of the typical midcycle gonadotropin surge, occurs in humans and monkeys. We investigated the potentially obligatory role of preovulatory P4 secretion in stimulating the midcycle LH surge by administering a potent P4 antagonist, RU 486(17 beta-hydroxy-11 beta-[4- dimethylaminophenyl-1]17 alpha-[prop-1-ynyl]estra-4,9-dien-3-one), to sexually mature, normally ovulatory cynomolgus monkeys on days 10-12 of the menstrual cycle (n = 18). Monkeys were randomized to receive RU 486 alone (5 mg/day, im; group I); RU 486 plus dexamethasone (1 mg/day, im; group II); dexamethasone alone (group III); or vehicle (ethanol; 0.5 ml; group IV). Before drug treatment, the follicular phases were quite similar among groups. The administration of RU 486 blocked (delayed) the expected gonadotropin surge, despite rising estrogen concentrations (greater than 250 pg/ml). The expected LH surge was delayed by RU 486 (n = 5) or RU 486 with dexamethasone (n = 3) until 36 +/- 7 (+/- SEM) and 27 +/- 8 days in groups I and II, respectively. In contrast, groups III (n = 3) and IV (n = 5) had timely midcycle surges after the administration of dexamethasone or vehicle alone (4 +/- 2 and 6 +/- 2 days, respectively). The intermenstrual interval was lengthened by RU 486 administration in both group I and II animals (61 +/- 6 and 54 +/- 6 days) compared to controls (30 +/- 2; P less than 0.0001). In summary, RU 486 effectively blocked imminent midcycle gonadotropin surges, delayed subsequent folliculogenesis, and significantly extended the menstrual cycle length. If RU 486 acted as a pure P4 antagonist, then P4 is necessary for timely midcycle gonadotropin surges to occur. However, recent evidence showing agonistic properties of RU 486 (in the virtual absence of P4) at both endometrial and pituitary levels may favor a P4-like (agonistic) blockade of the estrogen-induced FSH/LH surges by RU 486.

This article has been cited by other articles:

				S. J. Han, S. Y. Tsai, M.-J. Tsai, and B. W. O'Malley Distinct Temporal and Spatial Activities of RU486 on Progesterone Receptor Function in Reproductive Organs of Ovariectomized Mice Endocrinology, May 1, 2007; 148(5): 2471 - 2486. [Abstract] [Full Text] [PDF]

				E. M. Foecking, M. Szabo, N. B. Schwartz, and J. E. Levine Neuroendocrine Consequences of Prenatal Androgen Exposure in the Female Rat: Absence of Luteinizing Hormone Surges, Suppression of Progesterone Receptor Gene Expression, and Acceleration of the Gonadotropin-Releasing Hormone Pulse Generator Biol Reprod, June 1, 2005; 72(6): 1475 - 1483. [Abstract] [Full Text] [PDF]

				R. Leminen, T. Raivio, S. Ranta, J. Oehler, H. von Hertzen, O. A Janne, and O. Heikinheimo Late follicular phase administration of mifepristone suppresses circulating leptin and FSH - mechanism(s) of action in emergency contraception? Eur. J. Endocrinol., March 1, 2005; 152(3): 411 - 418. [Abstract] [Full Text] [PDF]

				C. De Geyter, M. De Geyter, P. R. Huber, E. Nieschlag, and W. Holzgreve Progesterone serum levels during the follicular phase of the menstrual cycle originate from the crosstalk between the ovaries and the adrenal cortex Hum. Reprod., April 1, 2002; 17(4): 933 - 939. [Abstract] [Full Text] [PDF]

				O.D. Slayden, K. Chwalisz, and R.M. Brenner Reversible suppression of menstruation with progesterone antagonists in rhesus macaques Hum. Reprod., August 1, 2001; 16(8): 1562 - 1574. [Abstract] [Full Text] [PDF]

				M. Mizuno, M. Gearing, and E. Terasawa The Role of Neuropeptide Y in the Progesterone-Induced Luteinizing Hormone-Releasing Hormone Surge in Vivo in Ovariectomized Female Rhesus Monkeys Endocrinology, May 1, 2000; 141(5): 1772 - 1779. [Abstract] [Full Text] [PDF]

				J. A. McCracken, E. E. Custer, and J. C. Lamsa Luteolysis: A Neuroendocrine-Mediated Event Physiol Rev, April 1, 1999; 79(2): 263 - 323. [Abstract] [Full Text] [PDF]

				P. E. Chappell, J. P. Lydon, O. M. Conneely, B. W. O' Malley, and J. E. Levine Endocrine Defects in Mice Carrying a Null Mutation for the Progesterone Receptor Gene Endocrinology, October 1, 1997; 138(10): 4147 - 4152. [Abstract] [Full Text] [PDF]

				E. Xiao, L. Xia-Zhang, D. Shanen, and M. Ferin Tonic Support of Luteinizing Hormone Secretion by Adrenal Progesterone in the Ovariectomized Monkey Replaced with Midfollicular Phase Levels of Estradiol J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2233 - 2238. [Abstract] [Full Text] [PDF]

				E. Baulieu Contragestion and other clinical applications of RU 486, an antiprogesterone at the receptor Science, September 22, 1989; 245(4924): 1351 - 1357. [Abstract] [PDF]